SG11202110534QA - Cd73 inhibitors - Google Patents

Cd73 inhibitors

Info

Publication number
SG11202110534QA
SG11202110534QA SG11202110534QA SG11202110534QA SG11202110534QA SG 11202110534Q A SG11202110534Q A SG 11202110534QA SG 11202110534Q A SG11202110534Q A SG 11202110534QA SG 11202110534Q A SG11202110534Q A SG 11202110534QA SG 11202110534Q A SG11202110534Q A SG 11202110534QA
Authority
SG
Singapore
Prior art keywords
inhibitors
Prior art date
Application number
SG11202110534QA
Inventor
Simon Bailey
Jianxia Feng
Dianjun Chen
Frank Kayser
Chong Liu
Hongbin Yuan
Original Assignee
Bioardis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioardis Llc filed Critical Bioardis Llc
Publication of SG11202110534QA publication Critical patent/SG11202110534QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202110534QA 2019-04-16 2020-04-03 Cd73 inhibitors SG11202110534QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/082816 WO2020210970A1 (en) 2019-04-16 2019-04-16 Imidazotriazine derivatives as cd73 inhibitors
PCT/CN2020/083233 WO2020211672A1 (en) 2019-04-16 2020-04-03 Cd73 inhibitors

Publications (1)

Publication Number Publication Date
SG11202110534QA true SG11202110534QA (en) 2021-11-29

Family

ID=72836784

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110534QA SG11202110534QA (en) 2019-04-16 2020-04-03 Cd73 inhibitors

Country Status (10)

Country Link
US (1) US20220204539A1 (en)
EP (1) EP3956341A4 (en)
JP (1) JP2022529152A (en)
KR (1) KR20210151923A (en)
CN (1) CN114286824A (en)
AU (1) AU2020258568A1 (en)
CA (1) CA3136367A1 (en)
SG (1) SG11202110534QA (en)
TW (1) TW202103710A (en)
WO (2) WO2020210970A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI821559B (en) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 A CD73 inhibitor, its preparation method and application
TW202131932A (en) * 2019-11-05 2021-09-01 美商博奥阿迪斯有限公司 Compounds as cd73 inhibitors
WO2023125681A1 (en) * 2021-12-29 2023-07-06 Beigene, Ltd. Heterocyclic compounds
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023220439A1 (en) * 2022-05-12 2023-11-16 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271058T1 (en) * 1996-10-09 2004-07-15 Pharmasset Ltd MYCOPHENOL BISPHOSPONATE COMPOUNDS
CN106536538A (en) * 2014-04-24 2017-03-22 共晶制药股份有限公司 2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2016069975A1 (en) * 2014-10-31 2016-05-06 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2017013956A (en) * 2015-05-01 2018-09-05 Cocrystal Pharma Inc Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer.
LT3399984T (en) * 2016-01-08 2023-11-10 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
US11058704B2 (en) * 2016-10-03 2021-07-13 Arcus Biosciences, Inc. Inhibitors of adenosine 5′-nucleotidase
WO2018183635A1 (en) * 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208980A1 (en) * 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN111094317B (en) * 2017-12-29 2023-03-31 上海和誉生物医药科技有限公司 Phosphonic acid derivative with CD73 inhibitory activity, and preparation method and application thereof

Also Published As

Publication number Publication date
EP3956341A1 (en) 2022-02-23
WO2020210970A1 (en) 2020-10-22
WO2020211672A1 (en) 2020-10-22
EP3956341A4 (en) 2023-01-04
CA3136367A1 (en) 2020-10-22
TW202103710A (en) 2021-02-01
CN114286824A (en) 2022-04-05
AU2020258568A1 (en) 2021-11-04
JP2022529152A (en) 2022-06-17
AU2020258568A8 (en) 2021-11-18
KR20210151923A (en) 2021-12-14
US20220204539A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
IL277006A (en) Cd73 inhibitors
IL283639A (en) Kif18a inhibitors
EP3843714A4 (en) Cd73 inhibitors
IL304348A (en) Cd73 inhibitors
GB201905265D0 (en) Inflammasome inhibition
IL292570B2 (en) Cd73 inhibitors
SG11202110534QA (en) Cd73 inhibitors
EP3999517A4 (en) Cd73 inhibitors
GB201819126D0 (en) Inhibitor compounds
IL290087A (en) Inhibitor compounds
IL276013A (en) Pi4kiiibeta inhibitors
GB201914860D0 (en) Inhibitor compounds
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
IL292095A (en) Thienopyrimidones as trpa1 inhibitors
IL292093A (en) Thienopyrimidones as trpa1 inhibitors
GB201905318D0 (en) Inhibitor compounds
GB201905328D0 (en) Inhibitor compounds
EP3745112C0 (en) Rotating-compensator ellipsometer
IL269414A (en) Rapar for safetyin taneis
GB201812462D0 (en) Inhibitors
GB201905370D0 (en) Elastate inhibition
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201901225D0 (en) Disclosure